Vepdegestrant in Phase 3: How Strong Are Its Chances?
What Is Vepdegestrant? Vepdegestrant (ARV-471) is a PROTAC® (Proteolysis Targeting Chimera)-based oral SERD designed to degrade estrogen receptor alpha (ERα),...
The BTK Degrader Revolution: How BeiGene’s BGB-16673 Could Redefine Blood Cancer Treatment with Phase III Breakthrough
Bruton’s tyrosine kinase (BTK) has been a cornerstone target in B‑cell malignancies for over a decade, but resistance to BTK...
Emerging Drug Developers Developing Cancer Targeting Exosomes
Exosomes are cell-derived nanovesicles, which are usually 50-150 nm in diameter and are involved in the intercellular transportation of materials....
Cancer Microbiome Targeting Emerging Drug Developers
Microbiome is an emerging player in cancer drug development. Recent research findings elicit varied roles of human gut microbiome, both...
Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to...